Chloe Botaine

Chloe Botaine

Biopharmaceutical Research Specialist
Chloe Botaine specializes in biopharmaceutical research and development, offering insights into the latest trends, challenges, and breakthroughs in biopharma. Her content covers topics such as drug discovery, clinical trials, and regulatory affairs. With a focus on advancing science and improving patient care, Chloe’s content contributes to the development of innovative therapies and medicines that address unmet medical needs and improve public health outcomes.
How Does RTI Surgical's $15M Expansion Boost Tissue Engineering?
Biotech & Bioprocessing How Does RTI Surgical's $15M Expansion Boost Tissue Engineering?

RTI Surgical recently unveiled a $15 million expansion of its Class III medical device facility in Alachua, Florida, marking a significant milestone in its commitment to advancing tissue engineering. This extensive overhaul includes the addition of a 5,000 square-foot clean room, drastically

Applications of Quantum Dots in Biotechnology
Biotech & Bioprocessing Applications of Quantum Dots in Biotechnology

Quantum dots, the nanoscale semiconductor particles that exhibit quantum mechanical phenomena, have emerged as a revolutionary tool in biotechnology. Due to their unique optical and electronic properties, quantum dots are being integrated into various applications, enhancing the capabilities of

Lonza Expands ADC Production with New Bioconjugation Suite in Switzerland
Management & Regulatory Lonza Expands ADC Production with New Bioconjugation Suite in Switzerland

Lonza has bolstered its presence in the field of antibody-drug conjugates (ADC) by extending its manufacturing collaboration with a renowned biopharma company. This strategic move involves the expansion of its bioconjugation operations at the Ibex Biopark located in Visp, Switzerland. Under this

Roche Ends UCB Partnership on Anti-Tau Alzheimer's Drug Bepranemab
Management & Regulatory Roche Ends UCB Partnership on Anti-Tau Alzheimer's Drug Bepranemab

Roche's recent decision to return the rights to UCB’s anti-tau antibody bepranemab comes after a four-year investment in the Alzheimer's disease drug candidate, which was initially valued at up to $2 billion in milestones. This strategic move happens just before the release of phase 2a data for the

AI Revolutionizes Early Drug Discovery with Precision and Efficiency
Research & Development AI Revolutionizes Early Drug Discovery with Precision and Efficiency

The modern biopharmaceutical industry is witnessing a significant transformation, thanks to the integration of artificial intelligence (AI) tools in early drug discovery. AI’s capabilities in managing and analyzing vast amounts of data generated from cell-based preclinical models through imaging

How Does the Retrogenix Non-Human Protein Library Aid Drug Discovery?
Research & Development How Does the Retrogenix Non-Human Protein Library Aid Drug Discovery?

Charles River Laboratories has taken a significant stride in the realm of biopharmaceutical research by launching the Retrogenix Non-Human Protein Library. This innovation is particularly designed to help clients assess the off-target interactions of their therapeutics with non-human proteins. The

Are Biopharma Companies Ready for Today's Regulatory Challenges?
Management & Regulatory Are Biopharma Companies Ready for Today's Regulatory Challenges?

Are Biopharma Companies Ready for Today's Regulatory Challenges? The biopharmaceutical sector is rapidly evolving, with companies constantly innovating to develop new treatments for a variety of diseases. However, navigating the regulatory landscape remains a significant challenge. Stricter

Can RNA Editing Revolutionize Genetic Therapy for AATD Patients?
Research & Development Can RNA Editing Revolutionize Genetic Therapy for AATD Patients?

RNA editing has long been a topic of fascination within the field of genetic research. Recent advancements by Wave Life Sciences have transformed this curiosity into a real-world application, with their trials showing promising results for treating alpha-1 antitrypsin deficiency (AATD). This

Will Trump or Harris Shape the Future of US Drug Pricing Reforms?
Management & Regulatory Will Trump or Harris Shape the Future of US Drug Pricing Reforms?

As the U.S. presidential election looms, the conversation around pharmaceutical policies intensifies, with Vice President Kamala Harris and former President Donald Trump proposing divergent paths. Harris and Trump represent fundamentally different approaches to drug pricing reforms, reflecting

Is Xeris Biopharma Holdings Inc a Promising Investment Opportunity?
Management & Regulatory Is Xeris Biopharma Holdings Inc a Promising Investment Opportunity?

The biotech industry is bustling with innovation and potential, and Xeris Biopharma Holdings Inc (NASDAQ: XERS) is making waves. This article aims to delve deep into the nuts and bolts of Xeris Biopharma’s recent market activities, financial health, insider trading, analysts' ratings, valuation

Loading

Subscribe to our weekly news digest.

Join now and become a part of our fast-growing community.

Invalid Email Address
Thanks for Subscribing!
We'll be sending you our best soon!
Something went wrong, please try again later